Allos Therapeutics reviews net loss of $20.

Therefore, relative to GAAP, Allos defers income recognition of sales to distributors until the product is sold through its distributors to health care providers. As such, Allos’ deferred revenue increased by $0.5 million through the 1st quarter of 2010, which represents the difference between non-GAAP gross product GAAP and sales sell-through sales for the first quarter 2010. As of March 31, 2010, Allos has documented total deferred revenue of $1.2 million. GAAP net revenue had been $7.4 million for the first quarter of 2010, which represents the $8.2 million of sell-through product sales net of $0.8 million of gross to net product sales adjustments.Related StoriesMeat-rich diet may increase kidney cancers riskFDA grants accelerated acceptance for Tagrisso to take care of sufferers with advanced NSCLCNew results reveal association between colorectal cancer and melanoma drug treatmentDeveloping antibodies to hinder CCR4-expressing cells, such as under the AT008 program, could provide a new highly targeted treatment to block cancer growth and pass on for a range of solid tumour types. Dr Phil L’Huillier, Cancer Research Technology’s director of business development, said: ‘This important license deal combines Cancer Research UK’s world-class research experience in the exciting region of chemokine research with the advancement of Affitech’s existing AT008 antibody programme.